Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the accumulation of abnormal beta-amyloid (Aβ) and hyperphosphorylated Tau (pTau). These proteinopathies disrupt neuronal activity, causing, among others, an excessive and hypersynchronous neuronal firing that promotes hyperexcitability and leads to brain network dysfunction and cognitive deficits. In this study, we used computational network modeling to build a causal inference framework to explain AD-related abnormal brain activity. We constructed personalized brain network models with a set of working points to enable maximum dynamical complexity for each brain. Structural brain topographies were combined, either with excitotoxicity, or postsynaptic depression, as two leading mechanisms of the Aβ and pTau on neuronal activity. By applying various levels of these putative mechanisms to the limbic regions that typically present, with the earliest and largest protein burden, we found that the excitotoxicity is sufficient and necessary to reproduce empirical biomarkers two biometrics associated with AD pathology: homotopic dysconnectivity and a decrease in limbic network dynamical fluidity. This observation was shown not only in the clinical groups (aMCI and AD), but also in healthy subjects that were virtually-diseased with excitotoxicity as these abnormal proteins can accumulate before the appearance of any cognitive changes. The same findings were independently confirmed by a mechanistic deep learning inference framework. Taken together, our results show the crucial role of protein burden-induced hyperexcitability in altering macroscopic brain network dynamics, and offer a mechanistic link between structural and functional biomarkers of cognitive dysfunction due to AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No. 785907 (SGA2), and No. 945539 (SGA3) Human Brain Project, and Virtual-BrainCloud (grant number 826421).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Only existing public datasets were used. In particular it is data from Sydney Memory and Ageing Study. https://cheba.unsw.edu.au/research-projects/sydney-memory-and-ageing-study
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All simulated data produced in the present study will be made available upon publication. All personalized data used in the present study are available upon reasonable request to the authors
